2249927-04-4
Chemical Structure
Ripertamab
Synonym(s): SCT400
- CAS No.: 2249927-04-4
- Formula:N/A
- Molecular Weight:(144.56 kDa)
IUPAC Name: N1-(3-chloro-2-(piperidin-1-yl)phenyl)-N4,N4-dimethylbenzene-1,4-disulfonamide
SMILES: [Ripertamab]
Biological Activity: Ripertamab (SCT400) is a recombinant human-mouse chimeric anti-CD20 IgG1κ monoclonal antibody. As an immunomodulator, ripertamab reduces the levels of pathogenic autoantibodies, alleviates immune complex deposition, and blocks the antigen-presenting function of cells. Ripertamab depletes CD20-positive cells. Ripertamab can induce infusion-related reactions, pulmonary toxicity, neutropenia and thrombocytopenia. Ripertamab is applicable to research related to non-Hodgkin's lymphoma, primary membranous nephropathy and idiopathic membranous nephropathy[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Ripertamab | ≥99.0% | Ripertamab (SCT400) is a recombinant human-mouse chimeric anti-CD20 IgG1κ monoclonal antibody. As an immunomodulator, ripertamab reduces the levels of pathogenic autoantibodies, alleviates immune complex deposition, and blocks the antigen-presenting function of cells. Ripertamab depletes CD20-positive cells. Ripertamab can induce infusion-related reactions, pulmonary toxicity, neutropenia and thrombocytopenia. Ripertamab is applicable to research related to non-Hodgkin's lymphoma, primary membranous nephropathy and idiopathic membranous nephropathy. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Crescioli S, et al. Antibodies to watch in 2025. MAbs. 2025;17(1):2443538. [Content Brief]
- [2]. Wang X, et al. Efficacy and safety of ripertamab for treating primary membranous nephropathy among adults: a multicenter, retrospective, real-world study. Front Immunol. 2025;16:1540694. Published 2025 Mar 26. [Content Brief]
- [3]. Li X, et al. The efficacy and safety of ripertamab in the treatment of idiopathic membranous nephropathy: a retrospective multicenter cohort study. Sci Rep. 2025;15(1):20567. Published 2025 Jul 1. [Content Brief]
